You have no items in your shopping cart.

Merck & Company: Product KL-798 (SPANISH)
Frey, Sherwood C. Jr.; Bodily, Samuel E.
Share This Product
Merck & Company: Product KL-798 (SPANISH)
Frey, Sherwood C. Jr.; Bodily, Samuel E. Case QA-0910 / Published October 11, 2017 / 5 pages. Collection: Darden School of Business
Format Price Quantity Select
PDF Download
$6.95
EPUB Download
$6.95
Printed Black & White Copy
$7.25

Product Overview

This is a Spanish translation of the June 14, 2016, version of UVA-QA-0582. Merck has been approached by a small biotech research firm with the proposal that Merck buy the rights to a new drug that promises to treat obesity and lower cholesterol. The drug is in the middle of phase I of the FDA approval process. Pat Harlow, the chief licensing officer, has been leading Merck's investigation team. A meeting is scheduled for tomorrow at which Merck's response to the offer will be drafted.




Select Format
Choose your delivery format to add this product to your cart or save it to your library. Please allow 10 minutes after purchasing for delivery of your electronic materials.
  • Videos List

  • Overview

    This is a Spanish translation of the June 14, 2016, version of UVA-QA-0582. Merck has been approached by a small biotech research firm with the proposal that Merck buy the rights to a new drug that promises to treat obesity and lower cholesterol. The drug is in the middle of phase I of the FDA approval process. Pat Harlow, the chief licensing officer, has been leading Merck's investigation team. A meeting is scheduled for tomorrow at which Merck's response to the offer will be drafted.

  • Learning Objectives

Related Products